Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences
November 26, 2018 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...
Molecular Templates, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
November 09, 2018 08:00 ET
|
Molecular Templates, Inc.
Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates,...
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Healthcare Conferences
September 26, 2018 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2018 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary...
Molecular Templates, Inc. Announces Pricing of Public Offering of Common Stock
September 20, 2018 20:41 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary...
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
September 19, 2018 16:01 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development...
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
September 19, 2018 08:00 ET
|
Molecular Templates, Inc.
The Agreement Will Support the Development of a Potential New Treatment Option for Multiple Myeloma AUSTIN, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) today...
Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results
August 09, 2018 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes
June 21, 2018 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, June 21, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...